Contact
searchSearch
HMP Global
Videos

Rethinking Embolic Protection in Peripheral Arterial Interventions

Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
03/18/2026

 

Watch as Dr Walker comments on the article by Drs Davis, Dovgan, and Dippel, "Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease.”

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates. 

Related Content

Original Research
Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease
03/18/2026
Tom Davis, MD; Peter Dovgan, MD; Eric J. Dippel, MD
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational...
03/18/2026
Vascular Disease Management
Clinical Editor's Corner
Expanding the Role of Embolic Protection in Peripheral Arterial Interventions
03/17/2026
Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
Dr Walker comments on "Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease.”
Dr Walker comments on "Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease.”
Dr Walker comments on "Temporary...
03/17/2026
Vascular Disease Management
Dr Marianne Brodmann speaks at ISET 2026
ISET 2026
Benefits of PTX: Insights from the TRUE-PTX Study
03/12/2026
Marianne Brodmann, MD
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results...
03/12/2026
Vascular Disease Management
Embolic Device
Fluidx Embolic IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting
02/10/2026
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc....
02/10/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Endovascular Devices
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML)
03/19/2026
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026...
03/19/2026
Vascular Disease Management
Neurovascular Care
Medtronic to Acquire Scientia Vascular, Marrying Access and Therapeutic Portfolios for Neurovascular Care
03/10/2026
Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'.
Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'.
Deal complements Medtronic's...
03/10/2026
Vascular Disease Management
VDM logo
Analysis
Artificial Intelligence Advances in Interventional Oncology: Year in Review
02/23/2026
Laura Simson, MA
02/23/2026
Vascular Disease Management
New Stroke Guidelines
New Guideline Expands Stroke Treatment for Adults, Offers First Pediatric Stroke Guidance
02/19/2026
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke...
02/19/2026
Vascular Disease Management
Radiation Safety
RAMPART Appoints Rob Williamson as Chief Revenue Officer
02/12/2026
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12,...
02/12/2026
Vascular Disease Management
The Salus and Tallahassee Memorial HealthCare teams celebrate after the first AeroShield case.
Radiation Protection Systems
Tallahassee Memorial HealthCare Advances Cath Lab Safety Through First-in-the-World Technology Adoption
02/10/2026
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee...
02/10/2026
Cath Lab Digest
Embolic Device
Fluidx Embolic IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting
02/10/2026
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc....
02/10/2026
Vascular Disease Management
Thrombectomy
Avantec Vascular, a NIPRO Company, Announces FDA 510(k) Clearance of Thrombectomy System
02/10/2026
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California...
02/10/2026
Cath Lab Digest
News
RAMPART Appoints Former Thoratec CEO Gary Burbach as Chairman of the Board
02/04/2026
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4,...
02/04/2026
Vascular Disease Management
Cardiovascular Scientific Forum
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
02/03/2026
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration...
02/03/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use